Emotion differentiation and negative emotional states: the mediating role of perceived academic control and the moderated effect of intrinsic motivation.

University students experience academic pressure, fatigue, and changes in their everyday and social lives during their transition into college. This study explored variables that influenced first-year students' stress, anxiety, and depression at a university in Chile. The remnant of long-term social unrest, which emerged at the end of the dictatorship in 1990, has lasted for more than three decades. It is present in the education sector and might reflect the negative emotional states that Chilean students still experience. In this way, students' capacity to distinguish and to regulate stress, anxiety, and depression is crucial, especially in contexts where intense negative emotional states occur; thus, more research is needed to achieve a richer understanding in academic settings. The study involved testing hypotheses over 6 months to undertake a regression-based path analysis using simple mediation and moderated mediation analysis. Results revealed that students' perceptions of their academic control mediated the relationship between their factor differentiation of emotional experiences and stress, anxiety, and depression. The indirect effect was statistically significantly moderated by intrinsic motivation. Consequently, the effect of their ability to differentiate emotions on stress, anxiety, and depression through the mediator changed due to the levels of intrinsic motivation. Implications and recommendations are discussed.

Percepción de la salud bucal en adultos mayores de la ciudad de Corrientes, Argentina / Perception of oral health in older adults in Corrientes, Argentina

Objetivo. Describir la percepción de la salud bucal en adultos mayores que asisten a Clubes de Abuelos y a una clínica odontológica universitaria. Métodos. Estudio descriptivo, transversal en la ciudad de Corrientes, Argentina, en 97 adultos mayores de 60 años. Se realizó un interrogatorio y el examen clínico bucodental. Para valorar la percepción de salud oral se utilizó el índice de Valoración en Salud Oral en Geriatría (GOHAI). Resultados. De los 97 adultos mayores que participaron, el 75,3% (n=73) correspondieron al sexo femenino. La edad media de la población fue de 67,1 ± 4,4 años, se observó que para el 86,4% la autopercepción de su salud bucal es negativa. Al comparar el grupo de adultos mayores que asisten a Clubes de Abuelos y los adultos mayores que asisten a la clínica odontológica se halló diferencias estadísticamente significativas en la percepción de la salud oral (p=0,0001). No se encontró asociación estadísticamente significativa con la edad (p=0,28), el sexo (p=0,50), el estado civil (p=0,45), el nivel de instrucción (p=0,06), la ocupación (p=0,68), el padecimiento de enfermedades sistémicas (p=0,52) y el índice de caries CPOD (p= 0,09). Conclusiones. En los adultos mayores que participaron del estudio predomina la percepción negativa de su salud oral, en especial en aquellos que buscaron atención odontológica.

Objective. Describe the perception of oral health in older adults who attend Grandparents' Clubs and a university dental clinic. Methods. Descriptive, cross-sectional study was conducted in the city of Corrientes, Argentina, in 97 adults over 60 years old. An interrogation and oral clinical examination were performed. To assess the perception of oral health, the Assessment Index in Oral Health in Geriatrics (GOHAI) was used. Results. The 97 older adults who participated, 75.3% (n=73) corresponded to the female sex. The mean age of the population was 67.1 ± 4.4 years, it was observed that for 86.4% the self-perception of their oral health is negative. When comparing the group of older adults who attend Grandparents' Clubs and the older adults who attend the dental clinic, statistically significant differences were found in the perception of oral health (p = 0.0001). No statistically significant association was found with age (p=0.28), sex (p=0.50), marital status (p=0.45), educational level (p=0.06), occupation (p=0.68), suffering from systemic diseases (p=0.52) and DMFT caries index (p=0.09). Conclusions. In the Older Adults who participated in the study, the negative perception of their oral health predominates, especially in those who sought dental care.

A esperança nos pais de criança com perturbação do espectro do autismo / Hope for parents of children with autism spectrum disorder

O diagnóstico de Perturbação do Espectro do Autismo (PEA) tem um grande impacto nos pais da criança, alterando as dinâmicas familiares com repercussões a vários níveis, onde a esperança parental sofre diversas oscilações ao longo do processo de transição entre o papel parental e o papel de cuidador. A esperança é um fator protetor da saúde mental, que impele a pessoa em direção aos seus objetivos, sendo importante que os profissionais de saúde compreendam de que forma esta é vivenciada pelos pais ao longo do processo de transição de papéis. O presente estudo, incide sobre a esperança dos pais de criança com PEA, tendo como objetivo compreender a perceção do fenómeno esperança pelos mesmos no processo de transição do papel parental para o papel de cuidador. Optou-se por um estudo de cariz qualitativo assente no Modelo de Transições de Afaf Meleis e na metodologia da Grounded Theory, para representar as variações e tipicidades do fenómeno, dirigida intencionalmente pelo processo de análise e comparação de dados. Neste sentido, os participantes do estudo foram selecionados de forma intencional através da técnica de bola de neve, a partir de uma associação de apoio a crianças com PEA. Foram entrevistadas no total sete mães. Como instrumento de colheita de dados recorreu-se à entrevista semiestruturada, à Escala de Esperança de Herth (HHI-PT) e ao Genograma da Esperança. No tratamento e análise dos achados foi utilizada a análise comparativa e codificação com recurso ao software de análise de dados qualitativos, WebQda. Desta análise emergiram seis categorias: Perceção de esperança, Impacto da situação de doença na esperança, fatores inibidores de esperança, fatores promotores de esperança, recursos de esperança e esperanças para a criança. Após a análise e comparação das mesmas, emergiu a categoria central: Vivendo a minha esperança em ti. Foi possível perceber que a perceção de esperança pelas mães é influenciada pelo impacto que a situação de doença tem nas mesmas. Este impacto traduz-se em reações emocionais, em necessidade de conhecimento e de habilidades parentais e em desesperança. A gestão deste impacto é facilitada por fatores promotores e recursos de esperança, mas também pode ser dificultada por fatores inibidores de esperança. A esperança das mães é projetada na sua criança, sendo influenciada pelo impacto que a situação de doença tem nas mães.

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients. OBJECTIVE: To determine whether ivermectin treatment can prevent hospitalization in individuals with early COVID-19. DESIGN, SETTING AND PARTICIPANTS: A randomized, double-blind, placebo-controlled study was conducted in non-hospitalized individuals with COVID-19 in Corrientes, Argentina. Patients with SARS-CoV-2 positive nasal swabs were contacted within 48 h by telephone to invite them to participate. The trial randomized 501 patients between August 19th 2020 and February 22nd 2021. INTERVENTION: Patients were randomized to ivermectin (N = 250) or placebo (N = 251) arms in a staggered dose, according to the patient's weight, for 2 days. MAIN OUTCOMES AND MEASURES: The efficacy of ivermectin to prevent hospitalizations was evaluated as primary outcome. We evaluated secondary outcomes in relationship to safety and other efficacy end points. RESULTS: The mean age was 42 years (SD ± 15.5) and the median time since symptom onset to the inclusion was 4 days [interquartile range 3-6]. The primary outcome of hospitalization was met in 14/250 (5.6%) individuals in ivermectin group and 21/251 (8.4%) in placebo group (odds ratio 0.65; 95% confidence interval, 0.32-1.31; p = 0.227). Time to hospitalization was not statistically different between groups. The mean time from study enrollment to invasive mechanical ventilatory support (MVS) was 5.25 days (SD ± 1.71) in ivermectin group and 10 days (SD ± 2) in placebo group, (p = 0.019). There were no statistically significant differences in the other secondary outcomes including polymerase chain reaction test negativity and safety outcomes. LIMITATIONS: Low percentage of hospitalization events, dose of ivermectin and not including only high-risk population. CONCLUSION: Ivermectin had no significant effect on preventing hospitalization of patients with COVID-19. Patients who received ivermectin required invasive MVS earlier in their treatment. No significant differences were observed in any of the other secondary outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT04529525 .

Evaluación de variables cardiovasculares en una población calchaquí de media y alta montaña de Tucumán / Evaluation of Cardiovascular Variables in a Calchaquí Population in the Middle and High Mountains of Tucumán

RESUMEN Introducción: La comunidad Quilmes (Tucumán) abarca 2400 habitantes de media y alta montaña (1800 a 4000 metros sobre el nivel del mar). El objetivo del presente trabajo fue conocer su estado de salud cardiovascular. Material y métodos: Se efectuó una investigación cuantitativa descriptiva transversal en personas pertenecientes a dicha comunidad que asistieron voluntariamente en los días 27 a 29 de septiembre de 2018 a la evaluación prevista. Resultados: Se estudiaron 202 pobladores (125 mujeres y 77 varones; 48 ± 1,4 años). El 23% de ellos tenían hipertensión arterial (HTA); un 14% eran tabaquistas; el 4,9% tenían diabetes (DBT); el 18% presentaba dislipidemia (DLP); el 25% consumía alcohol rutinariamente (1,0 ± 0,4 L/día). Asimismo, el 29% presentaba sobrepeso y el 36% obesidad. Se registró presión arterial (PA) elevada en 48 personas al momento del estudio. La PA disminuyó en la tercera toma con respecto a la primera, pero la frecuencia cardíaca aumentó en la tercera toma (74 ± 1 latidos por minuto vs. 77 ± 1; p <0,01). La saturación de O2 (95,0 ± 0,2%) se correlacionó negativamente con la edad (Pearson r: −0,266; p <0,001). En los pobladores con PA normal, la relación E/A determinada ecográficamente fue mayor (1,2 ± 0,0) y el espesor de la pared posterior del ventrículo izquierdo fue menor (8,5 ± 0.5 mm) que en aquellos con PA elevada (0,92 ± 0,1 y 9,0 ± 0.3, respectivamente, p <0,001). El 24% presentó placas ateroscleróticas y 120 pobladores presentaron DLP. Conclusiones: La población Quilmes presenta una prevalencia de factores de riesgo cardiovascular similar a la de centros urbanos, los que podrían llevar en los próximos años a un incremento de la morbimortalidad cardiovascular en esta población

ABSTRACT Background: The Quilmes community includes 2,400 inhabitants of the middle and high mountains of Tucumán (1,800 to 4,000 meters above sea level). The purpose of the present study was to know their cardiovascular health status. Material and methods: A cross-sectional descriptive quantitative investigation was carried out in people belonging to the Quilmes community who voluntarily attended the planned evaluation on September 27-29, 2018. Results: Two hundred and two settlers were studied (125 women and 77 men; 48 ± 1.4 years), 23% of them had hypertension (HTN); 14% were smokers; 4.9% had diabetes; 18% had dyslipidemia (DLP) and 25% usually consumed alcohol (1.0 ± 0.4 L/day). Also, 29% were overweight and 36% obese. High blood pressure (BP) was recorded in 48 individuals at the time of the study. Blood pressure decreased in the third compared to the first measurement, whereas heart rate increased in the third assessment (74 ± 1 beats per minute vs. 77 ± 1; p <0.01). Oxygen saturation (95.0 ± 0.2%) was negatively correlated with age (Pearson r: −0.266; p <0.001). In individuals with normal BP, ultrasound E/ratio was higher (1.2 ± 0.0) and left ventricular posterior wall thickness was lower (8.5±0.5 mm) than in those with elevated BP (0.92±0.1 and 9.0 ± 0.3, respectively, p <0.001). Twenty-four percent of individuals had atherosclerotic plaques and 120 had DLP. Conclusions: The Quilmes population presents a prevalence of cardiovascular risk factors similar to that of urban centers, which could lead to an increase in cardiovascular morbidity and mortality in the coming years

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.

OBJECTIVES: To assess the efficacy of ivermectin in addition to standard treatment compared to standard treatment alone in reducing hospitalizations in the COVID-19 patient population. TRIAL DESIGN: IVERCOR-COVID19 will be a single-center, prospective, randomized, double-blind, parallel group (1:1 ratio), placebo-controlled study. PARTICIPANTS: Patients who meet the following criteria will be invited to participate: Inclusion criteria: (1) Over 18 years of age who reside in the province of Corrientes at the time of diagnosis. (2) Confirmed diagnosis of COVID-19 by polymerase chain reaction (PCR) test for detection of SARS-CoV2 in the last 48 h. (3) In the case of women of childbearing age, they must be using a contraceptive method of proven efficacy and safety (barrier, hormonal, or permanent contraceptives) for at least 3 months prior to inclusion in the present study and for the entire period of time for the duration of the study and until at least 30 days after the end of this study. A woman will be considered to have no reproductive capacity if she is postmenopausal (at least 2 years without her menstrual cycles) or if she has undergone surgical sterilization (at least 1 month before the time of inviting her to participate in this study). (4) Weight at the time of inclusion greater than 48 kg. (5) That they sign the informed consent for participation in the study. EXCLUSION CRITERIA: (1) pregnant or breastfeeding women; (2) known allergy to ivermectin or some of the components of ivermectin tablets or placebo; (3) current use of home oxygen; (4) require hospitalization due to COVID-19 at the time of diagnosis or history of hospitalization for COVID-19; (5) presence of mal-absorptive syndrome; (6) presence of any other concomitant acute infectious disease; (7) known history of severe liver disease, for example liver cirrhosis; (8) need or use of antiviral drugs at the time of admission for another viral pathology other than COVID-19; (9) need or use of hydroxychloroquine or chloroquine; (10) use of ivermectin up to 7 days prior to randomization; (11) patients on dialysis or who have required it in the last 2 months or who plan to do it in the next 2 months; and (12) current participation or in the last 30 days in a research study that has included the administration of a drug (Table 1). Table 1 Ivermectin/placebo dose according to patient weight Patient weight Ivermectin/placebo dose Total dose (mg) Equal to or greater than 48 kg and less than 80 kg 2 tablets of 6 mg each at the time of inclusion and 2 tablets 24 h after the first intake 24 Equal or greater than 80 kg and less than 110 kg 3 tablets of 6 mg each at the time of inclusion and 3 tablets 24 h after the first intake 36 Equal or greater than 110 kg 4 tablets of 6 mg each at the time of inclusion and 4 tablets 24 h after the first intake 48 The study will be carried out by the Ministry of Public Health of the Province of Corrientes (Argentina) in coordination with the Institute of Cardiology of Corrientes in the Province of Corrientes, Argentina. INTERVENTION AND COMPARATOR: Intervention group: patients who are randomized to ivermectin will receive the dose according to their weight (patients up to 80 kg will receive 2 tablets of 6 mg ivermectin; patients with more than 80 kg and up to 110 kg will receive 3 tablets of 6 mg of ivermectin; patients weighing more than 110 kg will receive 4 tablets of 6 mg ivermectin) the day they enter the study and the same dose 24 h after the first dose. CONTROL GROUP: patients who are randomized to placebo will receive the dose according to their weight (patients up to 80 kg will receive 2 tablets of 6 mg placebo; patients with more than 80 kg and up to 110 kg will receive 3 tablets of 6 mg of placebo; patients weighing more than 110 kg will receive 4 tablets of 6 mg placebo) on the day they enter the study and the same dose 24 h after the first dose (Table 2). Table 2 Inclusion and exclusion criteria Inclusion criteria Exclusion criteria 1. Over 18 years of age who reside in the province of Corrientes at the time of diagnosis 1. Pregnant or breastfeeding women 2.Confirmed diagnosis of COVID-19 by polymerase chain reaction test for detection of SARS-CoV2 in the last 48 h 2. Known allergy to ivermectin or some of the components of ivermectin tablets or placebo 3. In case of being women of childbearing age, they must be using a contraceptive method of proven efficacy and safety (barrier, hormonal, or permanent contraceptives) for at least 3 months prior to inclusion in the present study, during the entire period of time for the duration of the study, and until at least 30 days after the end of this study. A woman will be considered to have no reproductive capacity if she is postmenopausal (at least 2 years without her menstrual cycles) or if she has undergone surgical sterilization (at least 1 month before the time of inviting her to participate in this study) 3. Current use of home oxygen 4. Weight at the time of inclusion equal to or greater than 48 kg 4. That require hospitalization due to COVID-19 at the time of diagnosis or history of hospitalization for COVID-19 5. That they sign the informed consent for participation in the study 5. Presence of mal-absorptive syndrome 6. Presence of any other concomitant acute infectious disease 7. Known history of severe liver disease, for example liver cirrhosis 8. Need or use of antiviral drugs at the time of admission for another viral pathology other than COVID-19 9. Need or use of hydroxychloroquine or chloroquine 10. Use of ivermectin up to 7 days prior to randomization 11. Patients on dialysis or who have required it in the last 2 months or who plan to do it in the next 2 months 12. Current participation or in the last 30 days in a research study that has included the administration of a drug MAIN OUTCOMES: Primary outcome will be the percentage of hospitalizations in patients with COVID-19 in the intervention and control groups. SECONDARY OUTCOMES: time to hospitalization in each of the arms of the study: number of days elapsed from the inclusion in the study until the hospitalization of the patient; percentage of use of invasive mechanical ventilation in each of the study arms: every patient who is connected to invasive mechanical ventilation after signing the informed consent and before the final study visit; time to invasive mechanical ventilation in each of the arms of the study: number of days elapsed from inclusion in the study to connection to invasive mechanical ventilation of the patient; percentage of patients requiring dialysis in each of the study arms: all patients who require renal replacement therapy of any kind, temporary or permanent, and which begins after signing the informed consent and before the final visit; mortality from all causes in each of the two trial groups: death of the patient, from any cause. Negative PCR swab at 3 ± 1 and 12 ± 2 days after entering the study. Ivermectin safety: it will be analyzed according to the incidence of adverse events that patients present in the intervention and control groups. The end of study (EOS) is recorded as the day the patient is discharged or death. Discharge will be granted according to the current recommendations of the Ministry of Public Health of the Province of Corrientes. A follow-up visit (EOF) will be made by phone 30 days after the EOS when vital status will be verified. RANDOMIZATION: Randomization will be done through a web system with randomly permuted blocks. Randomization will be carried out by one of the investigators who will not participate in the inclusion of patients or in the delivery of medication (Table 3). Table 3 EOS end of study, EOF end of follow-up Visit Basal and randomization, day 0 Day 3 ± 1 Day 12 ± 2 V#1 V#2 V#3 EOS EOF Informed consent X - - - - Inclusion/exclusion criteria X - - - - Demographic data and medical history X - - - - Concomitant medication X - - - - Vital signs* X X - - - Anthropometric data^ X - - - - Basal laboratory X - - - - PCR swab - X X - - Assessment of adverse events - X X X - Final objective evaluation - X X X X Randomization X - - - - Adherence to treatment X X - - - *Includes heart rate, temperature, and oxygen saturation by a digital saturometer ^Includes weight and height BLINDING (MASKING): The participants, investigators, care providers, and outcome assessors will be blinded. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): We will include a total of 500 patients (250 patients in each group). TRIAL STATUS: This is version 1.0, 17 August 2020. The recruitment started on 19 August 2020, and we anticipate the trial will finish recruitment on 31 December 2020. TRIAL REGISTRATION: ClinicalTrials.gov NCT04529525 . Registered on 26 August 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.

[Prevalence of pain among patients admitted to a clinical hospital]. / Prevalencia de dolor en la internación en un hospital de alta complejidad de Argentina.

BACKGROUND: Pain prevalence during hospital admission is variable, with estimates ranging from 32 to 77%. AIM: To determine pain prevalence during admission to a clinical hospital. MATERIAL AND METHODS: Patients admitted to medical and surgical wards were interrogated about the presence of pain within 48 to 72 hours after admission. Subjective pain was analyzed using a scale ranging from 0 to 10. Data was analyzed separately for medical, surgical, and obstetrical patients. RESULTS: A total of 736 patients aged 18 to 94 years (416 women) were recruited. Pain prevalence at 48 hours after admission was 56% (95% confidence intervals (CI (52.7 to 60.1). Pain prevalence in medical, surgical and obstetric patients was 37% (95% CI 31.4 to 42.1), 70% (95% CI 64.5 to 75.5) and 77% (95% CI 68.6 to 84), respectively. The median pain intensities in medical, surgical, and obstetrical patients were 7 (interquartile range (IQR) 6-8), 7 (IQR 5-8) y 7 (IQR 5-8), respectively. CONCLUSIONS: The prevalence of pain among patients admitted to the hospital is high, especially in obstetric and surgical units.

Prevalencia de dolor en la internación en un hospital de alta complejidad de Argentina / Prevalence of pain among patients admitted to a clinical hospital

Background: Pain prevalence during hospital admission is variable, with estimates ranging from 32 to 77%. Aim: To determine pain prevalence during admission to a clinical hospital. Material and Methods: Patients admitted to medical and surgical wards were interrogated about the presence of pain within 48 to 72 hours after admission. Subjective pain was analyzed using a scale ranging from 0 to 10. Data was analyzed separately for medical, surgical, and obstetrical patients. Results: A total of 736 patients aged 18 to 94 years (416 women) were recruited. Pain prevalence at 48 hours after admission was 56% (95% confidence intervals (CI (52.7 to 60.1). Pain prevalence in medical, surgical and obstetric patients was 37% (95% CI 31.4 to 42.1), 70% (95% CI 64.5 to 75.5) and 77% (95% CI 68.6 to 84), respectively. The median pain intensities in medical, surgical, and obstetrical patients were 7 (interquartile range (IQR) 6-8), 7 (IQR 5-8) y 7 (IQR 5-8), respectively. Conclusions: The prevalence of pain among patients admitted to the hospital is high, especially in obstetric and surgical units.

Técnica de desproteinización para el tratamiento de hipoplasias / Collagen removal technique for treating dental enamel hypoplasia

La hipoplasia del esmalte es una anomalía estructural originada por la formación incompleta o defectuosa de la matriz del esmalte dentario. Se manifiesta como defectos macroscópicos que varían desde línas tenues hasta cavidades de diferentes tamaños. Las propuestas terapéuticas son variadas y abarcan desde la remineralización de la lesión hasta la exodoncia de la pieza afectada. Frente a los reiterados fracasos de las restauraciones en molares hipoplásicos debido al pobre patrón de grabado que presentan, el objetivo de este trabajo es mostrar una alternativa para el tratamiento restaurador de estas piezas dentarias, mejorando la adhesión.

Litiasis vesicular en pacientes colecistectomizados. Hospital San Jose de Chincha, 2013 / Cholelithiasis in cholecystectomy patients. San Jose Hospital of Chincha, 2013

Objetivos: Determinar las características clinicas, socio demograficas y de laboratorio de la litiasis vesicular en pacientes colecistectomizados. Materiales y métodos: Se realizó un estudio descriptivo, de tipo retrospectivo, donde se revisaron 142 historias clínicas, de pacientes portadores de colelitiasis, que fueron operados en el hospital "San José" de Chincha entre Enero y Diciembre del 2013. Resultados: Se encontró que el sexo femenino fue más frecuente en un 73.9%, con un predominio sobre los varones en 2.8/1, las edades más frecuentes en ambos sexos se presentaron entre la tercera y cuarta década de vida, presentándose un incremento de casos después de los 60 años de edad en varones. El sobrepeso se pre-sentó en el 57.0%. La multiparidad y la ingesta de anticonceptivos alcanzaron un 73.34% y 56.9% respectiva-mente. En la bioquímica sanguínea se halló el incremento de triglicéridos con un 51.94% y la disminución del colesterol HDL con un porcentaje de 57.42%. Los valores de colesterol total y glucosa sanguínea no guarda-ron relación con la colelitiasis. Conclusiones: Los factores más frecuentes relacionados con la génesis de litiasis vesicular fueron, el sexo femenino, la presencia de sobrepeso, la multiparidad y la ingesta de anti-conceptivos. La dislipidemia establecida por el incremento de triglicéridos y la disminución del colesterol HDL son factores importantes. (AU)

Objectives: To determine the clinical characteristics and demographic partner of gallstones in chole-cystectomy patients. Materials and Methods: A descriptive, retrospective, where 142 medical records of patients with cholelithiasis, who were operated in the "San José" of Chincha hospital between January and December 2013. Results: were reviewed was made: it was found that female gender was more frequent in 73.9%, with a predominance of males in 2.8 / 1, the most common age in both sexes occurred between the third and fourth decade of life, presenting an increase in cases after 60 age in males. Overweight occurred in 57.0%. Multiparity and intake of contraceptive reached 73.34% and 56.9% respectively. In blood chemistry increased with 51.94% triglycerides and decreased HDL cholesterol with a percentage of57.42% was found. The values of total cholesterol and blood glucose levels were not related to cholelithiasis. Conclusions: They are more frequent factors related to the genesis of gallstones were female gender, the presence of overweight, multiparity and intake of contraceptives. Dyslipidemia established by increased triglycerides and decreased HDL cholesterol are important factors. (AU)

El rol social de la donación de sangre. Un caso de detección de brucelosis / The social role of the blood donation. Detection's case of brucellosis

En el siguiente artículo se expondrá, a partir del análisis de un caso clínico hallado en el Servicio de Hemoterapia del Hospital Materno infantil San Roque (Paraná, Entre Ríos). la importancia de la donación de sangre como factor fundamental en la detección de patologías encubiertas o desconocidas para un donan­te. En el caso en cuestión y, a partir de pertenecer a una zona endémica, se reconoce la importancia en la detección de un caso de Brucelosis.

In the following article it will be exposed, from the analysis a clinical case, found in the Service of Hemoterapia of the infantile Maternal Hospital San Roque (Paraná, Entre Ríos), the importance of the donation of blood like fundamental factor in the detection of concealed pathologies or strangers for a donor. In the case at issue and, from belonging to an endemic zone, the importance in the detection of a case of Brucelosis is recognized.

Relations between Internet use, socio-economic status (SES), social support and subjective health.

This study aimed to explore relations between Internet use, socio-economic status (SES), social support and subjective health. Participants were from representative samples between 15 and 80 years of age from seven different European countries. Two different survey datasets were used: (i) eHealth trends (eHT; N = 7934) and (ii) the European social survey (ESS2; N = 11248). Internet users who had used the Internet for health purposes were compared with Internet users who had not used it for health purposes. Structural equation modelling was used to assess the relationships between SES, Internet use, social support and subjective health. Use of other media was compared to Internet use in relation to social support and subjective health. Internet use was found to be more closely related to social support and subjective health than use of other media. Internet use was also found to be a plausible mediator between SES and subjective health, especially through interacting with social support.

Pseudomyxoma peritonei: a rare differential diagnosis of hydrosalpinx.

OBJECTIVE: To establish the diagnosis of a right hydrosalpinx in a woman with primary infertility. DESIGN: Case report. SETTING: Departments of Obstetrics and Gynecology and Surgery, academic medical center and teaching hospital. PATIENT(S): A healthy 41-year-old woman with a history of primary infertility and a possible right hydrosalpinx. INTERVENTION(S): Operative laparoscopy, disconnection of right hydrosalpinx, peritoneal biopsies. MAIN OUTCOME MEASURE(S): Establishment of diagnosis with peritoneal biopsies. RESULT(S): The patient was diagnosed with peritoneal pseudomyxoma peritonei, which required further treatment. CONCLUSION(S): Malignancies, although rare, should always be part of the differential diagnosis of external causes of tubal disease.